It’s only been a few years since Arcutis began generating revenue, but the Thousand Oaks-based biotechnology company believes it is quickly becoming “an undisputed leader in medical dermatology,” and analysts are beginning to believe it as well. Shares of Arcutis soared 27% Oct. 29, after the company shared its financial results for the third quarter…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
